f Immunogenic Presentation of a Conserved gp41 Epitope of Human Immunodeficiency Virus Type 1 on Recombinant Surface Antigen of Hepatitis B Virus
- Authors: Leopold Eckhart, Wolfgang Raffelsberger, Boris Ferko, Annelies Klima, Martin Purtscher, Hermann Katinger, Florian Rüker
- Author for correspondence: Florian Rüker. Fax +43 1 36 006 6652, e-mail firstname.lastname@example.org,ac.at
- J. Gen. Virol., September 1996 77: 2001-2008, doi: 10.1099/0022-1317-77-9-2001
- Subject: Animal - RNA viruses
- Published Online:
In view of the high antigenic variability of human immunodeficiency virus type 1 (HIV-1), a vaccine against AIDS must induce an immune response to epitopes as invariable as possible among the various virus strains and clones. Previously the highly conserved six amino acid sequence Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) from gp41, defining the epitope of the human MAb 2F5, was shown to elicit HIV-1-neutralizing antibodies when presented on haemagglutinin of influenza virus. We investigated the immunogenic potential of the MAb 2F5 epitope and two of its major escape epitopes as internal fusions to the hepatitis B virus (HBV) surface antigen (HBsAg). Recombinant HBsAg-HIV proteins produced in the methylotrophic yeast Pichia pastoris self-assembled into 22 nm lipoprotein particles. Mice immunized with these particles developed an anti-HBsAg immune response in a range that is considered to be protective against HBV infection in humans. More importantly, antisera had extremely high titres of antibodies reactive with a structurally flexible form of the HIV-1 epitope, whereby strong cross-reactivity with the escape variants of the epitope was observed. Although HIV-1 gp160 and the ectodomain of gp41 containing the epitope were significantly recognized, the antisera failed to neutralize HIV-1 in vitro. These data, together with those on the haemagglutinin-ELDKWAS fusion suggest that the ability of the MAb 2F5 epitope to induce neutralizing antibodies depends on the molecular context in which it is presented. Therefore, further characterization of secondary and tertiary structure requirements of the epitope is indispensable for the full exploitation of its potential as a vaccine component.
© Society for General Microbiology Ltd 1996 | Published by the Microbiology Society
Article metrics loading...
Full text loading...
Author and Article Information
/content/journal/jgv/10.1099/0022-1317-77-9-2001dcterms_title,dcterms_subject,pub_serialTitlepub_serialIdent:journal/jgv AND -contentType:BlogPost64
/content/journal/jgv/10.1099/0022-1317-77-9-2001dcterms_title,dcterms_subject-pub_serialIdent:journal/jgv AND -contentType:BlogPost64
Figure data loading....